A randomized, double blind, comparative study of vitamin D3 versus placebo in patients with epithelial ovarian cancer to prevent relapse after operation and chemotherapy

A randomized, double blind, comparative study of vitamin D3 versus placebo in patients with epithelial ovarian cancer to prevent relapse after operation and chemotherapy - Amateras VII

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000002637

Enrollment

250

Registered

2009-11-01

Start date

2009-11-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ovarian cancer

Interventions

vitamin D3 placebo

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: 1. First operation with or without chemotherapy for ovarian cancer at Jikei University hospitals and no residual tumor is observed. 2. Obtained informed consent 3. Age 20 and more and less than 80 years old

Exclusion criteria

Exclusion criteria: 1. Already taking vitamin D supplement or 1,25 vitamin D 2. History of kidney stone 3. Other difficulties judged by the surgeon in charge

Design outcomes

Primary

Measure	Time frame
total death	—

Secondary

Measure	Time frame
relapse	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026